Biohaven Pharmaceutical Holding Current Ratio 2016-2022 | BHVN

Current and historical current ratio for Biohaven Pharmaceutical Holding (BHVN) from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations. Biohaven Pharmaceutical Holding current ratio for the three months ending June 30, 2022 was 1.75.
Biohaven Pharmaceutical Holding Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-06-30 $1.17B $0.67B 1.75
2022-03-31 $1.17B $0.58B 2.03
2021-12-31 $0.88B $0.53B 1.64
2021-09-30 $0.94B $0.46B 2.04
2021-06-30 $0.67B $0.40B 1.67
2021-03-31 $0.90B $0.40B 2.28
2020-12-31 $0.60B $0.28B 2.17
2020-09-30 $0.71B $0.22B 3.26
2020-06-30 $0.36B $0.17B 2.18
2020-03-31 $0.47B $0.12B 3.89
2019-12-31 $0.00B 0.00
2019-09-30 $0.42B $0.05B 8.96
2019-06-30 $0.47B $0.05B 10.62
2019-03-31 $0.23B $0.02B 9.60
2018-12-31 $0.27B $0.02B 13.94
2018-09-30 $0.18B $0.02B 11.99
2018-06-30 $0.23B $0.01B 17.84
2018-03-31 $0.12B $0.02B 6.80
2017-12-31 $0.14B $0.01B 14.49
2017-09-30 $0.18B $0.02B 8.12
2017-06-30 $0.21B $0.02B 11.91
2017-03-31 $0.05B $0.02B 3.44
2016-12-31 $0.02B $0.01B 3.03
2016-09-30 $0.00B 0.00
2016-06-30 $0.00B 0.00
2016-03-31 $0.00B 0.00
2015-12-31 $0.00B $0.00B 5.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $10.904B $0.463B
Biohaven Pharmaceutical is a commercial-stage biotechnology company focused on developing, and commercializing products, primarily in the fields of central nervous system diseases, including neurological and rare disorders.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $150.237B 9.11
GSK (GSK) United Kingdom $58.285B 7.00
Bio-Rad Laboratories (BIO.B) United States $12.433B 27.47
QIAGEN (QGEN) Netherlands $9.287B 15.55
Ginkgo Bioworks Holdings (DNA) United States $5.158B 0.00
Arcus Biosciences (RCUS) United States $1.868B 36.47
Myovant Sciences (MYOV) United Kingdom $1.655B 0.00
Emergent Biosolutions (EBS) United States $1.024B 5.93
ADC Therapeutics SA (ADCT) Switzerland $0.370B 0.00
Zymeworks (ZYME) Canada $0.319B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
Gelesis Holdings (GLS) United States $0.079B 0.00
SQZ Biotechnologies (SQZ) United States $0.068B 0.00
Ambrx Biopharma (AMAM) United States $0.041B 0.00